Epithalon DSIP Thymosin Alpha-1 ET10 ET50 DS5 DS15 TA5 TA10 SS-31 2S10 2S50
TDS 31 Inquiries
12656-61-0
Pharmaceutical Grade
99%
shenzhen
sc
5mg/ 10 mg/15 mg/ 50mg. 10 bottles per box
2027-12-31
tr
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Cerebrolysin
Other Name:Cerebrolysin;FPE 1070
CAS No.:12656-61-0
EC Number:1592732-453-0
Categories:
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
tr
-
Location:
B27 SHING LEE COMM BLDG 8WING KUT ST CENTRAL HONGKONG
-
Average lead Time:
1
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History31 Inquiries
Country Product Purchase Quantity Date Posted
India
High Quality cerebrolysin FPE 1070 Cerebrolysin powder 99% white powder 12656-61-0 Quanjinci
28 KG Sep 26, 2023
United States
CEREBROLYSIN
1 MT Mar 10, 2026
United Kingdom
Cerebrolysin (CBL60)
10 MG Jun 18, 2026
Brazil
Cerebrolysin
60 MG Apr 21, 2026
United States
Cerebrolysin
1 KG Mar 23, 2026
United States
Cerebrolysin
500 G Feb 9, 2026
South Africa
Cerebrolysin
1 KG Dec 29, 2025
United States
cerebrolysn
10 MG Dec 5, 2025
United States
Cerebrolysin
50 G Jul 17, 2025
Ireland
Cerebrolysin
1 Nov 4, 2024
United States
Cerebrolysin
1 G Jul 24, 2026
United States
Cerebrolysin
10 G Jul 8, 2026
United States
Cerebrolysin
5 G Jun 29, 2026
Ireland
cerebrolysin
1 L Jun 26, 2026
United States
cerebrolysin
3 PCS May 13, 2026
South Africa
Cerebrolysin
1 KG Dec 29, 2025
United States
Cerebrolysin POWDER
1 G Dec 2, 2025
United Kingdom
Cerebrolysin Raw Powder
10 G Nov 3, 2025
South Korea
Cerebrolysin
1 G Jun 21, 2024
Uzbekistan
CEREBROLYSIN
1 KG Sep 22, 2023 Post an enquiry for this product